| 5.34 -0.71 (-11.74%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.23 | 1-year : | 9.61 |
| Resists | First : | 7.05 | Second : | 8.23 |
| Pivot price | 5.67 |
|||
| Supports | First : | 2.76 | Second : | 0.1 |
| MAs | MA(5) : | 5.84 |
MA(20) : | 5.35  |
| MA(100) : | 1.97 |
MA(250) : | 8.1 |
|
| MACD | MACD : | 0.9 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 59.1 |
D(3) : | 63.5 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 35 | Low : | 0.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ASBP ] has closed above bottom band by 31.8%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.01 - 6.04 | 6.04 - 6.06 |
| Low: | 5.22 - 5.25 | 5.25 - 5.27 |
| Close: | 5.3 - 5.34 | 5.34 - 5.38 |
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Thu, 28 May 2026
Aspire Biopharma Issues Shareholder Letter - Yahoo Finance
Wed, 27 May 2026
Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for - PharmiWeb.com
Wed, 27 May 2026
Under-the-tongue caffeine sticks to reach EoS gym members - Stock Titan
Wed, 13 May 2026
Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program - Yahoo Finance
Fri, 08 May 2026
Sublingual Drug Reformulator Expands into Caffeine Market & Gets Capital Injection - Streetwise Reports
Thu, 07 May 2026
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.2e+006 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 805.9 % |
| Return on Equity (ttm) | 119.5 % |
| Qtrly Rev. Growth | 34550 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -552.39 |
| Qtrly Earnings Growth | -7.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 75960 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|